Related references
Note: Only part of the references are listed.Ex Vivo Model of Meningococcal Bacteremia Using Human Blood for Measuring Vaccine-Induced Serum Passive Protective Activity
Joyce S. Plested et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra
Keith S. Reisinger et al.
CLINICAL AND VACCINE IMMUNOLOGY (2009)
Phase III Comparison of an Investigational Quadrivalent Meningococcal Conjugate Vaccine with the Licensed Meningococcal ACWY Conjugate Vaccine in Adolescents
Lisa A. Jackson et al.
CLINICAL INFECTIOUS DISEASES (2009)
Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease
Dan M. Granoff
VACCINE (2009)
Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
Carl E. Frasch et al.
VACCINE (2009)
Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005
Mehmet Ceyhan et al.
VACCINE (2007)
Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
David S. Stephens et al.
LANCET (2007)
Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
Cressida Auckland et al.
JOURNAL OF INFECTIOUS DISEASES (2006)
Meningococcal surrogates of protection - serum bactericidal antibody activity
R Borrow et al.
VACCINE (2005)
Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom
R Borrow et al.
INFECTION AND IMMUNITY (2003)
Importance of complement source in measuring meningococcal bactericidal titers
GF Santos et al.
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY (2001)
Share Paper
